195 related articles for article (PubMed ID: 21239475)
21. Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks.
Takemura H; Rao VA; Sordet O; Furuta T; Miao ZH; Meng L; Zhang H; Pommier Y
J Biol Chem; 2006 Oct; 281(41):30814-23. PubMed ID: 16905549
[TBL] [Abstract][Full Text] [Related]
22. Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors.
Nguyen TN; Saleem RS; Luderer MJ; Hovde S; Henry RW; Tepe JJ
ACS Chem Biol; 2012 Jan; 7(1):172-84. PubMed ID: 22004065
[TBL] [Abstract][Full Text] [Related]
23. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.
Hickson I; Zhao Y; Richardson CJ; Green SJ; Martin NM; Orr AI; Reaper PM; Jackson SP; Curtin NJ; Smith GC
Cancer Res; 2004 Dec; 64(24):9152-9. PubMed ID: 15604286
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
Bryant HE; Helleday T
Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
[TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors.
Pires IM; Ward TH; Dive C
Br J Pharmacol; 2010 Mar; 159(6):1326-38. PubMed ID: 20128802
[TBL] [Abstract][Full Text] [Related]
26. D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.
Juang SH; Lung CC; Hsu PC; Hsu KS; Li YC; Hong PC; Shiah HS; Kuo CC; Huang CW; Wang YC; Huang L; Chen TS; Chen SF; Fu KC; Hsu CL; Lin MJ; Chang CJ; Ashendel CL; Chan TC; Chou KM; Chang JY
Mol Cancer Ther; 2007 Jan; 6(1):193-202. PubMed ID: 17237279
[TBL] [Abstract][Full Text] [Related]
27. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
28. X-ray structures of checkpoint kinase 2 in complex with inhibitors that target its gatekeeper-dependent hydrophobic pocket.
Lountos GT; Jobson AG; Tropea JE; Self CR; Zhang G; Pommier Y; Shoemaker RH; Waugh DS
FEBS Lett; 2011 Oct; 585(20):3245-9. PubMed ID: 21907711
[TBL] [Abstract][Full Text] [Related]
29. Irofulven induces replication-dependent CHK2 activation related to p53 status.
Wang Y; Wiltshire T; Senft J; Reed E; Wang W
Biochem Pharmacol; 2007 Feb; 73(4):469-80. PubMed ID: 17118344
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.
Tao Y; Zhang P; Girdler F; Frascogna V; Castedo M; Bourhis J; Kroemer G; Deutsch E
Oncogene; 2008 May; 27(23):3244-55. PubMed ID: 18084327
[TBL] [Abstract][Full Text] [Related]
32. Caffeine inhibits the checkpoint kinase ATM.
Blasina A; Price BD; Turenne GA; McGowan CH
Curr Biol; 1999 Oct; 9(19):1135-8. PubMed ID: 10531013
[TBL] [Abstract][Full Text] [Related]
33. Requirement for NBS1 in the S phase checkpoint response to DNA methylation combined with PARP inhibition.
Horton JK; Stefanick DF; Zeng JY; Carrozza MJ; Wilson SH
DNA Repair (Amst); 2011 Feb; 10(2):225-34. PubMed ID: 21130714
[TBL] [Abstract][Full Text] [Related]
34. Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonine-68 and down-regulation of Cdc6 expression.
Yin MB; Li ZR; Cao S; Durrani FA; Azrak RG; Frank C; Rustum YM
Mol Pharmacol; 2004 Jul; 66(1):153-60. PubMed ID: 15213307
[TBL] [Abstract][Full Text] [Related]
35. Anticancer therapy with checkpoint inhibitors: what, where and when?
Garrett MD; Collins I
Trends Pharmacol Sci; 2011 May; 32(5):308-16. PubMed ID: 21458083
[TBL] [Abstract][Full Text] [Related]
36. Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: checkpoint activation as a strategy against cancer.
Chen CR; Wang W; Rogoff HA; Li X; Mang W; Li CJ
Cancer Res; 2005 Jul; 65(14):6017-21. PubMed ID: 16024600
[TBL] [Abstract][Full Text] [Related]
37. Targeting chk2 kinase: molecular interaction maps and therapeutic rationale.
Pommier Y; Sordet O; Rao VA; Zhang H; Kohn KW
Curr Pharm Des; 2005; 11(22):2855-72. PubMed ID: 16101442
[TBL] [Abstract][Full Text] [Related]
38. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.
Veuger SJ; Curtin NJ; Richardson CJ; Smith GC; Durkacz BW
Cancer Res; 2003 Sep; 63(18):6008-15. PubMed ID: 14522929
[TBL] [Abstract][Full Text] [Related]
39. Part I: Design, synthesis and biological evaluation of novel pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors with studying their activities alone and in combination with genotoxic drugs.
Galal SA; Abdelsamie AS; Shouman SA; Attia YM; Ali HI; Tabll A; El-Shenawy R; El Abd YS; Ali MM; Mahmoud AE; Abdel-Halim AH; Fyiad AA; Girgis AS; El-Diwani HI
Eur J Med Chem; 2017 Jul; 134():392-405. PubMed ID: 28433679
[TBL] [Abstract][Full Text] [Related]
40. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
Tse AN; Schwartz GK
Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
